Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/Leucovorin in Metastatic Colorectal Cancer

Clinical Cancer Research

Volumn 10, Issue 6, 2004, Pages 1949-1955

  Van Zuylen, Lia ^a   Bridgewater, John ^b   Sparreboom, Alex ^a   Eskens, Ferry A L M ^a   De Bruijn, Peter ^a   Sklenar, Ivo ^c   Planting, Andre S T ^a   Choi, Les ^c   Bootle, Douglas ^c   Mueller, Christian ^c   Ledermann, Jonathan A ^b   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; POLYAMINE SYNTHESIS INHIBITOR; SAM 486A; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FLUSHING; HAND FOOT SYNDROME; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PARESTHESIA; PERITONEUM PSEUDOMYXOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SOMNOLENCE; STOMATITIS;

ADULT; AGED; AMIDINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INDANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PSEUDOMYXOMA PERITONEI; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 12144289431     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-02-0995     Document Type: Article

References (22)

1. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988;48:759-74.
2. Regenass U, Caravatti G, Mett H, et al. New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity. Cancer Res 1992;52:4712-8.
3. Regenass U, Mett H, Stanek J, Mueller M, Kramer D, Porter CW, CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 1994;54:3210-7.
4. Manni A, Badger B, Wechter R, Kunselman S, Rossini A, Demers L. Biochemical and growth-modulatory effects of the new S-adenosylmethionine decarboxylase inhibitor CGP 48 664 in malignant and immortalized human breast epithelial cells in culture. Int J Cancer 1995;62:485-91.
5. Gutman M, Beltran PJ, Fan D, et al. Treatment of nude mice with 4-amidinoindan-1-one-2′-amidinohydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastases of human melanoma cells. Melanoma Res 1995;5:147-54.
6. Thomas T, Faaland CA, Adhikarakunnathu S, Thomas TJ. Structure-activity relations of S-adenosyldecarboxylase inhibitors on the growth of MCF-7 breast cancer cells. Breast Cancer Res Treat 1996;39:293-306.
7. Delworth MG, Nishioka K, Pettaway C, et al. Systemic administration of 4-amidinoindanon-1-(2′-amidino)/hydrazone, a new inhibitor of S-adenosyl methionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncology 1997;6:293-9.
8. Paridaens R, Uges DR, Barbet N, et al. A Phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer 2000;83:594-601.
9. Eskens FALM, Greim GA, Van Zuylen C, et al. Phase I and pharmacologic study of weekly administration of the polyamine synthesis inhibitor SAM486A (CGP 48 664) in patients with solid tumors. Clin Cancer Res 2000;6:1736-43.
10. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer (Phila.) 1997;80:1179-87.
11. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
12. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
13. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;16:2938-47.
14. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
15. Wallace HM, Caslake R. Polyamines and colon cancer. Eur J Gastroenterol Hepatol 2001;13:1033-9.
16. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997;2:808-15.
17. Goodman S, Zahurak M, Piantadosi S. Some practical improvements in the continual reassessment method for Phase I studies. Stat Med 1995;14:1149-61.
18. Schaaf LJ, Ferry DG, Hung CT, Perrier DG, Edwards IR. Analysis of 5′-deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1985; 342:303-13.
19. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Investig New Drugs 1990;8:57-63.
20. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investig New Drugs 1992;10:239-53.
21. Wattanatorn W, Mc Leod HL, Macklon F, Cassidy J, Kendle KE, Reid M. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer. Pharmacotherapy 1997;17:881-6.
22. Siu LL, Rowinsky EK, Hammond L, et al. A Phase I and pharmacokinetic (PK) study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with solid malignancies. Clin Cancer Res 2002;8:2157-66.